Patent Expiration

2001-2015 NCEs—Anti-Infective Drugs Arranged according to the approval year in alphabetical order of generic names.

Caspofungin Acetate Ertapenem Sodium Tenofovir Disoproxil Fumarate Adefovir Dipivoxil Micafungin Sodium Nitazoxanide Pazuﬂoxacin Mesylate Pruliﬂoxacin Voriconazole Cancidas® Invanz® Viread® Hepsera® Funguard®/Mycamine® Alinia® Pazucross®/Pasil® Sword® Vfend®

O H2N O O

NH2 OH O S O- HO • + F NH O Na F O OH OH N O NH2 O HO H O O O N HO O H H N O N OH NH OH N N O O H2N F H N O NH - N N O H2N OH H2N N N O O N O OH N HO O S O O O O N N O N N . + O N N N HN OH Na O P O O O F O NH H N O HO NO2 N N O N HN O S HO NH OH O O O HN S O O O P O N O N H • CH COOH O HO OH O HO N N 3 2 O O H O HO . NH CH SO H OH . O O O N 3 3 OH O O F HOOC COOH O HO

Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company 2015/7/26 (US) 2016/5/21 (US) 2018/1/25 (US) 2014/9/2 (US) 2019/3/16 (US) 1993/4/13 (US) 2009/4/13 (US) 2009/2/4 (US) 2016/5/24 (US) 2001 $573 Million 2001 $569 Million 2001 $1,108 Million 2002 $97 Million 2002 N/A 2002 N/A 2002 N/A 2002 N/A 2002 $682 Million 2014/3/9 (EU) 2013/2/2 (EU) 2017/7/25 (EU) 2011/9/10 (EU) 2015/9/29 (EU) No rights (EU) No rights (EU) 2008/10/26 (EU) 2011/1/24 (EU) (US) (Y2015) (US) (Y2015) (US) (Y2015) (US) (Y2015) (JP) (Y2015) (US) (Y2015) (JP) (Y2015) (JP) (Y2015) (US) (Y2015) 2014/3/10 (CN) 2013/2/4 (CN) 2017/7/25 (CN) No rights (CN) 2015/9/29 (CN) No rights (CN) No rights (CN) 2008/11/5 (CN) 2011/2/2 (CN) Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: A lipopeptide antifungal drug acted as glucan synthesis inhibitor A β-lactam antibiotic used to treat moderate to severe bacterial A reverse transcriptase inhibitor used to treat HIV infection and A nucleotide analog reverse transcriptase inhibitor used to treat An inhibitor of the synthesis of fungal cell walls 1,3-beta-D-glucan An antiprotozoal agent used to treat diarrhea caused by Giardia A quinolone antibacterial agent used for the intravenous therapy An inhibitor of bacterial DNA gyrase used to treat urinary tract A triazole antifungal agent used to treat serious, invasive fungal to treat fungal infections. infections. HBV infection. HBV infection. as antifungal drug. lamblia or Cryptosporidium parvum. of several infections. infections. infections.

Atazanavir Sulfate Daptomycin Emtricitabine Fosamprenavir Calcium Fosfluconazole Gemifloxacin Mesylate Sertaconazole Nitrate Doripenem Hydrate Eberconazole Nitrate Reyataz® Cubicin® Emtriva® Lexiva®/Telzir® Prodif® Factive® Ertaczo®/Dermofix®/Zalain® Finibax®/Doribax® Ebernet®

HOOC O O O - O - NH HN O O HO P OH O O O 2+ . P NH O Ca OH N HN N NH N H N O 2 O F N H H 2 NH2 O l Cl H N N OH C O CONH O O COOH O N N O O 2 O NH N O N N O OH O H H NH S S H H N N S N N N O N N HO O N N N N NH2 N N N O H H O F O N N O O O S O O O F Cl O H COOH HN H2N S NH N Cl H H NH Cl O O O OH OH NH HN N O O O HNO HNO3 O 3 H O N H2SO4 O OH . 2 NH CH3SO3H 2 O F

Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company 2017/6/20 (US) 2016/6/15 (US) 2016/3/29 (US) 2017/12/24 (US) 2017/3/25 (US) 2017/4/4 (US) 2014/5/31 (US) 2015/6/5 (US) 2010/4/9 (US) 2003 $1,139 Million 2003 $1,127 Million 2003 N/A 2003 $99.5 Million 2003 N/A 2003 N/A 2003 N/A 2005 N/A 2005 N/A 2017/4/14 (EU) No rights (EU) 2011/1/31 (EU) 2018/3/10 (EU) 2017/1/27 (EU) 2015/6/14 (EU) 2005/2/1 (EU) 2012/8/18 (EU) 2010/4/4 (EU) (US) (Y2015) (US) (Y2015) (US) (Y2015) (US) (Y2015) (JP) (Y2015) (US) (Y2015) (US) (Y2015) (JP) (Y2015) (ES) (Y2015) 2017/4/14 (CN) No rights (CN) 2011/1/31 (CN) 2018/3/9 (CN) 2017/1/27 (CN) 2015/6/15 (CN) No rights (CN) 2012/8/20 (CN) No rights (CN) Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: An antiretroviral drug of the protease inhibitor (PI) class used to A lipopeptide antibiotic used to treat complicated skin infections A nucleoside reverse transcriptase inhibitor (NRTI) used for the A prodrug of amprenavir as a protease inhibitor used to treat HIV A water-soluble phosphate prodrug of fluconazole used to treat A quinolone antibiotic used to treat acute bacterial exacerbation An imidazole class antifungal used to treat skin infections such as A β-lactam class drug used for bacterial infections with ultra-broad An azole antifungal agent used to treat cutaneous fungal treat HIV infection. and staphylococcus aureus bloodstream infections. treatment of HIV infection. infections. fungal infections. of chronic bronchitis and community-acquired pneumonia. athlete's foot. antibiotic spectrum. infections.

Entecavir Hydrate Luliconazole Posaconazole Tigecycline Tipranavir Anidulafungin Clevudine Darunavir Ethanolate Telbivudine Baraclude® Lulicon®/Luzu® Noxaﬁl® Tygacil® Aptivus® Eraxis®/Ecalta® Levovir®/Revovir® Prezista® Tyzeka®/Sebivo®

O N OH N CF3 H Cl N O HO OH HO O O O H O O H N OH N N N H N NH2 O H H OH N HN O CN H N OH OH O S F OH O H N N O N O O N N H O NH O H O N H2N N N S HO H S HO F N N NH2 O O O NH Cl S N N O O O O O O HN H OH O O OH N OH HO N H2O N OH O OH O O N HO F C2H5OH N H N O OH N HO HO HO

Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company 2015/8/21 (US) 2016/7/5 (US) 2019/7/19 (US) 2016/4/9 (US) 2019/12/22 (US) 2020/2/17 (US) 2014/1/28 (US) 2015/2/13 (US) 2023/9/11 (US) 2005 $1,312 Million 2005 N/A 2005 $487 Million 2005 $304 Million 2005 N/A 2006 N/A 2006 N/A 2006 $1,810 Million 2006 N/A 2011/10/18 (EU) 2016/7/5 (EU) 2014/12/20 (EU) 2012/8/21 (EU) 2015/5/4 (EU) 2013/3/18 (EU) 2015/1/30 (EU) 2013/8/24 (EU) No rights (EU) (US) (Y2015) (JPS) (Y2015) (EU) (Y2015) (US) (Y2015) (US) (Y2015) (US) (Y2015) (KR) (Y2015) (US) (Y2015) (CH) (Y2015) 2011/10/18 (CN) 2016/7/5 (CN) 2014/12/20 (CN) 2012/10/3 (CN) 2015/5/4 (CN) 2013/3/18 (CN) 2015/1/30 (CN) No rights (CN) 2023/8/6 (CN) Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: An oral antiviral drug used in the treatment of HBV infection. A topical antifungal imidazole with broad-spectrum used to treat A blocker of the synthesis of ergosterol used as antifungal drug. A glycylcycline antibiotic used to treat gram-positive and - A nonpeptidic protease inhibitor (PI) used to treat HIV infection. An echinocandin antifungal drug used to treat Candidemia and A nucleoside analog as antiviral drug used for the treatment of A protease inhibitor used to treat HIV infection. A synthetic thymidine nucleoside analogue as antiviral drug used cutaneous mycoses. negative bacterial infections. other forms of Candida infections. HBV infection. to treat HBV infection.

Maraviroc Raltegravir Potassium Retapamulin Ceftobiprole Medocaril Sodium Etravirine Sitaﬂoxacin Hydrate Levornidazole Ceftaroline Fosamil Acetate Laninamivir Octanoate Hydrate Selzentry®/Celsentri® Isentress® Altabax®/Altargo® Zeftera®/Zevtera® Intelence® Gracevit® 优诺安® Teﬂaro®/Zinforo® Inavir®

CN CN OH O O N O + N N O O O O N K O OH H N N H N - 2 H F N HO N H O F N S OH OH N H O F N N N N S S N P N O OH N O S F H H O N N N l HO O S N H N O C N HO H N N O O N N O HN N N O N O O N NH N - O O 1.5 H O H O O O O l 2 O S S 2 HN NH2 O O C O2N N • CH COOH O O • Br 3 O - + H2N • O NH O Na F H2O NH2

Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company 2021/8/6 (US) 2023/10/3 (US) 2018/10/27 (US) 2017/12/8 (US) 2020/12/13 (US) 2013/12/24 (US) No rights (US) 2018/12/17 (US) 2017/7/17 (US) 2007 $189.7 Million 2007 $1,511 Million 2007 N/A 2008 N/A 2008 N/A 2008 N/A 2009 N/A 2010 N/A 2010 N/A 2021/5/9 (EU) 2022/10/21 (EU) 2018/10/27 (EU) 2017/12/11 (EU) 2019/9/24 (EU) 2009/4/26 (EU) No rights (EU) 2018/12/17 (EU) 2017/7/22 (EU) (US) (Y2015) (US) (Y2015) (US) (Y2015) (CA) (Y2015) (US) (Y2015) (JP) (Y2015) (CN) (Y2015) (US) (Y2015) (JP) (Y2015) 2021/5/9 (CN) 2022/10/21 (CN) 2018/10/27 (CN) 2017/12/18 (CN) 2019/9/24 (CN) 2009/4/27 (CN) No rights (CN) 2018/12/17 (CN) 2017/7/22 (CN) Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: A C-C chemokine receptor-5 (CCR5) antagonist used to treat HIV A HIV-1 integrase inhibitor used to treat HIV infection. A protein synthesis inhibitor as antibacterial agent used to treat A cephalosporin antibiotic used to treat skin and soft tissue A non-nucleoside reverse transcriptase inhibitor (NNRTI) used to A fluoroquinolone antibiotic used in the treatment of various A nitroimidazole derivative used to treat infectious diseases A cephalosporin antibiotic used to treat acute bacterial skin A long acting neuraminidase inhibitor used to treat influenza infection. bacterial skin infections. infections. treat HIV infection. infections. caused by sensitive anaerobic bacteria. infections and pneumonia. infection .

Peramivir Hydrate Boceprevir Rilpivirine Hydrochloride Telaprevir Bedaquiline Fumarate Cobicistat Dolutegravir Sodium Eﬁnaconazole Elvitegravir Rapiacta®/Peramiﬂu® Victrelis® Edurant® Incivek®/Incivo®/Telavic® Sirturo® Tybost® Tivicay® Jublia® Vitekta®

O OH H2N NH CN H • + N - Na HO O O Br CH O O HN CN H N 3 N N O O N N N O N H N N H HO O F F OH N H N O O O N N F N NH2 O O H H N N NH N N S OH H H O O COOH N N N O N N H OH O O O . H H O NH N O N H F O O HN N NH NH O O HOOC F 3 H2O • S O N HCl Cl

(JP) (Y2015) (US) (US) (Y2015) PHARMACEUTICAL COMPANIES (US) (Y2015) (US) (Y2015) PHARMACEUTICAL COMPANIES (EU) (Y2015) (US) (Y2015) (CA) (Y2015) (EU) (Y2015) (Y2015) OF No rights (CN) 2021/7/19 (CN) 2022/8/9 (CN) OF 2021/8/31 (CN) 2023/7/18 (CN) 2027/7/6 (CN) 2026/4/28 (CN) 2014/5/2 (CN) 2023/11/20 (CN) Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: A neuraminidase inhibitor used for the treatment of influenza. A protease inhibitor used for the treatment of HCV infection. A non-nucleoside reverse transcriptase inhibitor (NNRTI) used to A protease inhibitor as antiviral agent used to treat HCV A proton-translocating ATP synthetase inhibitor used to treat A CYP3A inhibitor used to inhibit liver enzymes that metabolize A HIV-1 integrase strand transfer inhibitor (INSTI) used to treat A triazole antifungal used to treat onychomycosis. An integrase inhibitor used to treat HIV infection. treat HIV infection. infection. tuberculosis. other medications of anti-HIV. HIV infection.

Simeprevir Sodium Sofosbuvir Asunaprevir Daclatasvir Dihydrochloride Delamanid Morinidazole Oritavancin Diphosphate Tavaborole Vaniprevir Olysio®/Sovriad® Sovaldi® Sunvepra® Daklinza® Deltyba® 迈灵达® Orbactiv® Kerydin® Vanihep®

Cl HO O NH O HO NH O 2 HO OH H S O H O O N O N O O O NH O O2N O Cl O O S O O F O H O OH N O N O O O O O O F OH O N H N O N O O O N H O NH HN NH O F N N H O S H N B N O N O HN P O N H N O O Cl S O H H HN HN H O O N O F N O N HN O2N O N OH O NH O N N N CO2H HO O N H H H O F . Na O H HN N O O HO O HN O . 2 HCl OH O O NH N H O O OH HO H O O H H N O HN 2 NH Cl . H 2 H3PO4

2026/7/28 (CN) PHARMACEUTICAL COMPANIES Examination (CN) 2023/5/20 (CN) 2027/8/9 (CN) 2023/10/10 (CN) N/A (CN) 2015/1/27 (CN) 2015/5/26 (CN) 2026/7/14 (CN) OF Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: Profile: A NS3/4A protease inhibitor used to treat HCV infection. A nucleotide analogue HCV NS5B polymerase inhibitor used to A HCV NS3/4A protease inhibitor used to treat HCV infection. A HCV NS5A replication complex inhibitor used to treat HCV A bactericidal agent used to treat multi-drug resistant A nitroimidazoles antibiotic used to treat bacterial infections A novel semisynthetic glycopeptide antibiotic used for treatment An oxaborole antifungal drug used for the topical treatment of A HCV NS3/4A protease inhibitor used to treat HCV infection. treat HCV infection. infection. tuberculosis (MDR-TB). including appendicitis and pelvic inflammatory disease. of serious Gram-positive bacterial infections. onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes. Dasabuvir Sodium Hydrate Isavuconazonium Sulfate Exviera® Cresemba®

O F F N S . Na+ HO N O . N H2O N E N IOS NC N 关注药渡官方微信 + N O N • - O HSO4 Drug A-Z APP E N O O S N O N O H H 获取全球新药上市信息、研发数据 N O Android 微信号 : Pharmacodia Approval Patent Expiration Sales Company Approval Patent Expiration Sales Company Global Drug R & D in your pocket 2029/5/17 (US) 2020/10/31 (US) 2015 N/A 2015 N/A 2028/9/17 (EU) 2020/10/25 (EU) (EU) (Y2015) (US) (Y2015) 2028/9/17 (CN) 2020/10/25 (CN) Proﬁle: Proﬁle: A HCV NS5B RNA polymerase inhibitor used to treat HCV infection The prodrug of isavuconazole used to treat invasive aspergillosis Copyright © 2016 Pharmacodia (Beijing) Co., LTD. All rights reserved. in combination with other medicinal products. and invasive mucormycosis.